Quite a few analysts from Wall Street have expected the stocks of MRNA to post a sales sum of $$.57 billion for the current quarter. Accordingly, six investment analysts have also provided the brokerage with the earnings estimate of the company, with the lowest range coming in at $2.87 billion, and the highest coming in at $5.56 billion. The sales reported by the company last year were $66.35 million, which indicates an annual growth rate of about 6,787.7%. The company will be publishing its next quarterly report on the 4th of August.
The Quarterly Estimates Of MRNA
Interestingly, MRNA had previously posted their quarterly report on the 6th of May. The company had reported an EPS of $2.84 for the quarter, which was more than the consensus estimate of $2.04. The revenue generated by the company over the quarter was $1.94 billion, which was slightly less than the consensus estimate of $2.48 billion. The return on equity for the company was 19.76% with the net margin set at 21.90%.
There have been quite a few research equities that have commented on the stocks of MRNA. SVB Leerink has already reaffirmed its rating of sell in an 18th April research report. Morgan Stanley has also reduced the price target of the company from $201 to $190 with a rating of equal weight in a 7th May research report.
Chardan Capital has also increased the price target of the company from $182 to $188 with a rating of buy in a 7th May research report. The Bank of America has put forward a rating of sell, with a price target of $140 in a 26th February research report.
Three of the investment analysts commenting on the company have issued it with a rating of sell, while seven others have given the company a rating of hold. Around eight other analysts have issued the company with a rating of buy. Currently, MRNA has a hold rating with a $162.88 price target.